6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week

Chart, Trading, Courses, Forex, Analysis

Image Source: Pixabay

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index have market capitalizations ranging from $87M to $542M and average $269M. They were UP 3.9%, on average, last week and are now only UP 9.4% YTD. They are ranked below in descending order as to their performances.

  1. Mind Medicine (MNMD): UP 8.2% last week
  2. Compass Pathways (CMPS): UP 4.0% last week
  3. GH Research (GHRS): UP 3.8% last week
  4. Atai (ATAI): No Change last week
  5. Seelos (SEEL): No Change last week
  6. Incannex Healthcare (IXHL): DOWN 0.7% last week

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL) of 23 such stocks of which the majority have market capitalizations of less than $50M. It was UP 11.0% last week but remains DOWN 2.2% YTD.

More By This Author:

Canadian Cannabis LPs Up 20% Last Week - Here's Why
Cannabis MSO Stocks Jumped 40% Last Week - Here's Why
Bubble In AI "Penny" Stocks Pricked In August

Disclosure: None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.